EI
ABBV icon

Ethic Inc’s AbbVie ABBV Stock Holding History

Ethic Inc’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21M Buy
83,563
+2,843
+4% +$612K 0.26% 57
2026
Q1 		$17.6M Buy
80,720
+8,264
+11% +$1.83M 0.27% 63
2025
Q4 		$16.6M Buy
72,456
+3,141
+5% +$716K 0.25% 68
2025
Q3 		$16M Buy
69,315
+3,535
+5% +$720K 0.26% 65
2025
Q2 		$12M Sell
65,780
-2,017
-3% -$375K 0.21% 92
2025
Q1 		$14M Sell
67,797
-29,888
-31% -$5.81M 0.28% 66
2024
Q4 		$17.4M Buy
97,685
+10,120
+12% +$1.86M 0.35% 45
2024
Q3 		$15.9M Sell
87,565
-7,114
-8% -$1.33M 0.4% 38
2024
Q2 		$16.2M Buy
94,679
+7,114
+8% +$1.18M 0.38% 43
2024
Q1 		$15.9M Buy
87,565
+48,995
+127% +$8.44M 0.4% 38
2023
Q4 		$5.98M Buy
38,570
+3,574
+10% +$521K 0.18% 130
2023
Q3 		$5.22M Buy
34,996
+2,683
+8% +$394K 0.18% 128
2023
Q2 		$4.35M Sell
32,313
-3,888
-11% -$570K 0.16% 150
2023
Q1 		$5.77M Sell
36,201
-552
-2% -$84.4K 0.23% 100
2022
Q4 		$5.94M Sell
36,753
-15,719
-30% -$2.41M 0.32% 70
2022
Q3 		$7.04M Buy
52,472
+3,837
+8% +$551K 0.48% 31
2022
Q2 		$7.45M Buy
48,635
+16,766
+53% +$2.56M 0.52% 25
2022
Q1 		$5.17M Buy
31,869
+12,163
+62% +$1.77M 0.36% 60
2021
Q4 		$2.67M Buy
19,706
+755
+4% +$89.2K 0.21% 119
2021
Q3 		$2.04M Buy
18,951
+10,064
+113% +$1.15M 0.21% 125
2021
Q2 		$1M Sell
8,887
-3,471
-28% -$391K 0.12% 208
2021
Q1 		$1.34M Sell
12,358
-4,016
-25% -$430K 0.24% 103
2020
Q4 		$1.75M Sell
16,374
-3,060
-16% -$294K 0.46% 37
2020
Q3 		$1.7M Buy
19,434
+4,374
+29% +$412K 0.65% 30
2020
Q2 		$1.48M Buy
15,060
+4,264
+39% +$375K 0.84% 21
2020
Q1 		$823K Buy
10,796
+760
+8% +$64.7K 0.69% 35
2019
Q4 		$889K Buy
+10,036
New +$833K 0.65% 36

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Ethic Inc's ABBV Position: Q2 2026 in Review

Ethic Inc increased its AbbVie (ABBV) stake by 3.5% in Q2 2026, buying an estimated $612K and bringing the position to 83,563 shares worth $21M. The position accounts for 0.26% of the portfolio, ranked #57.

Ethic Inc first reported a position in ABBV in Q4 2019 and has held it in 27 quarters since. 4,221 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Ethic Inc held 83,563 shares of AbbVie worth $21M as of Q2 2026.
  • Ethic Inc bought 2,843 AbbVie shares in Q2 2026, an estimated $612K.
  • AbbVie made up 0.26% of Ethic Inc's portfolio in Q2 2026, its #57 holding.
  • Ethic Inc first reported a position in AbbVie in Q4 2019 and has held it in 27 quarters since.
  • 4,221 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Ethic Inc's 13F filing for Q2 2026, filed 29 Jul 2026.